PXL065

A novel stereoisomer of pioglitazone for the treatment of type 2 diabetes

PXL065 is a novel stereoisomer of the thiazolidinedione class of medications, specifically a deuterated form of pioglitazone. It is being developed for the treatment of type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and high blood sugar levels.

Chemical Structure and Mechanism

Chemical structure of deuterated pioglitazone

PXL065 is a deuterated form of pioglitazone, which means that certain hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification is intended to improve the pharmacokinetic properties of the drug, potentially enhancing its efficacy and reducing side effects.

Pioglitazone, the parent compound, is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It works by increasing the sensitivity of cells to insulin, thereby lowering blood glucose levels. PXL065 retains this mechanism of action but is designed to offer a more favorable safety profile.

Development and Clinical Trials

PXL065 is currently undergoing clinical trials to evaluate its safety and efficacy in patients with type 2 diabetes. The development of PXL065 is part of a broader effort to create improved versions of existing drugs through the use of deuteration, which can lead to better drug stability and reduced metabolism.

Potential Benefits

The use of deuterium in PXL065 aims to provide several potential benefits over traditional pioglitazone:

• Improved Metabolic Stability: Deuterium can slow the rate of drug metabolism, potentially leading to longer-lasting effects and reduced dosing frequency.
• Reduced Side Effects: By altering the metabolic pathway, PXL065 may reduce the risk of side effects commonly associated with pioglitazone, such as weight gain and fluid retention.
• Enhanced Efficacy: The improved pharmacokinetic profile may enhance the drug's ability to lower blood glucose levels effectively.

Related Pages

• Type 2 diabetes mellitus
• Thiazolidinedione
• Pioglitazone
• Peroxisome proliferator-activated receptor